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Abstract
There is great potential to be explored regarding the use of agent-based modelling and simulation as an
alternative paradigm to investigate early-stage cancer interactions with the immune system. It does not
suffer from some limitations of ordinary differential equation models, such as the lack of stochasticity,
representation of individual behaviours rather than aggregates and individual memory. In this paper
we investigate the potential contribution of agent-based modelling and simulation when contrasted with
stochastic versions of ODE models using early-stage cancer examples. We seek answers to the following
questions: (1) Does this new stochastic formulation produce similar results to the agent-based version?
(2) Can these methods be used interchangeably? (3) Do agent-based models outcomes reveal any benefit
when compared to the Gillespie results? To answer these research questions we investigate three well-
established mathematical models describing interactions between tumour cells and immune elements.
These case studies were re-conceptualised under an agent-based perspective and also converted to the
Gillespie algorithm formulation. Our interest in this work, therefore, is to establish a methodological
discussion regarding the usability of different simulation approaches, rather than provide further biological
insights into the investigated case studies. Our results show that it is possible to obtain equivalent
models that implement the same mechanisms; however, the incapacity of the Gillespie algorithm to
retain individual memory of past events affects the similarity of some results. Furthermore, the emergent
behaviour of ABMS produces extra patters of behaviour in the system, which was not obtained by the
Gillespie algorithm.
Introduction
In previous work, three case studies using established mathematical models of immune interactions with
early-stage cancer were considered in order to investigate the additional contribution of ABMS to ODE
models simulation [1]. These case studies were re-conceptualised under an agent-based perspective and
the simulation results were compared with those from the ODE models. Our results showed that, apart
from the well known differences between these approaches (as those outlined for example, in Schieritz
and Milling [2]), further insight from using ABMS was obtained, such as extra population patterns of
behaviour.
In this work we apply the Gillespie algorithm [3, 4], which is a variation of the Monte Carlo method,
to create stochastic versions of the original ODE models investigated in [1]. We aim to reproduce the
variability embedded in the ABMS systems to the mathematical formulation and verify whether results
resemble each other. In addition, due to the fact that the Gillespie algorithm also regards integer quan-
tities for their elements, we hope that this method overcomes some differences observed when comparing
atomic agents represented in the ABMS with possible fractions of elements observable in the ODE results.
To the best of our knowledge, current literature regarding the direct comparison of the Gillespie
algorithm and ABMS is scarce. We want therefore to answer research questions such as: (1) Does this new
stochastic formulation produce similar results to ABMS? (2) Can these methods be used interchangeably
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the extra patterns revealed by the ABMS? We aim to establish a methodological discussion regarding the
benefits of each approach for biological simulation, rather than provide further insights into the biological
aspects of the problems studied. We therefore intend to compare the dynamics of each approach and
observe the outcomes produced over time. We hope that this study provides further insights into the
potential usability and contribution of ABMS to systems simulation.
Case Studies
The case studies used for our comparison regard models with different population sizes, varying modelling
effort and model complexity. We hope that by tackling problems with different characteristics, a more
robust analysis of our experiments is performed. The features of each case study are shown in Table 1.
The first case study considered is based on an ODE model involving interactions between generic
tumour and effector cells. The second case study adds to the previous model the influence of the IL-
2 cytokine molecules in the immune responses. The third case study comprises a model of interactions
between effector cells, tumour cells, and IL-2 and TGF-β molecules. For all case studies, three approaches
are presented: the original mathematical model, its conversion into the Gillespie algorithm model and
the ABMS model. To answer our research questions, the Gillespie and ABMS approaches outcomes are
compared. Our results show that for most cases the Gillespie algorithm does not produce outcomes
statistically similar to the ABMS. In addition, Gillespie is incapable to reproduce the extreme patterns
observed in the ABMS outcomes for the last case study.
The remainder of this paper is organized as follows. The next section introduces the literature review
comparing stochastic ODE models and ABMS for different simulation domains. First, we show general
work that has been carried out in areas such as economics and operations research, and then we focus
on research concerned with the comparison for immunological problems. Finally, we discuss gaps in the
literature regarding cancer research. In the following section we introduce our Gillespie and agent-based
modelling development processes and the methods used for conducting the experimentation. Subsequently
we present our case studies, comparison results and discussions. In the final section we draw our overall
conclusions and outline future research opportunities.
Related Work
Current in-silico approaches used in early-stage cancer research include computational simulation of com-
partmental models, individual-based models and rule-based models. Compartmental models adopt an
aggregate representation of the elements in the system. They include deterministic methods such as
ordinary differential equation (ODE) models, system dynamics (SD) models and partial differential equa-
tion (PDE) models. These models have been largely employed in the study of dynamics between cancer
cells and tumour cells [5, 6], therapies for cancer [7], tumour responses to low levels of nutrients [8–11]
and tumour vascularization [12, 13]. Although these models have been very useful to understand and
uncover various phenomena, they present several limitations. For instance, they do not encompass emer-
gent behaviour and stochasticity. In addition, it is difficult to keep a record of individual behaviour
and memory over the simulation course [14, 15]. Stochastic compartmental models include Monte Carlo
simulation models, which are computational algorithms that perform random sampling to obtain nu-
merical results [16]. Amongst others, they are useful for simulating biological systems, such as cellular
interactions and the dynamics of infectious diseases [17]. As these methods rely on stochastic process to
produce their outputs, they overcome some of the limitations of the deterministic compartmental models,
as they allow for variability of outcomes. The individuals in these models, however, do not have any sort
of memory of past events. Rule-based models are a relatively new research area mostly focused on mod-
elling and simulating biochemical reactions, molecular interactions and cellular signalling. The literature
3regarding the application of rule-based models to interactions between the immune system and cancer
cells, however, is scarce. Individual-based models, or agent-based modelling and simulation (ABMS),
relax the aggregation assumptions present in compartmental approaches and allow for the observation of
the behavior of the single cells or molecules involved in the system. This approach has also been applied
to early-stage cancer research [1, 18].
The differences between deterministic compartmental models and individual-based models are well
known in operations research [2, 19–21] and have also been studied in epidemiology [22, 23] and system’s
biology [24–26]. Deterministic compartmental models assume continuous values for the individuals in
the system, whereas in ABMS individual agents are represented. This peculiarity of each approach
highly impacts the simulation results similarity depending on the size of the populations [1]. There is
still however the need for further investigations between the interchangeable use of some Monte Carlo
methods and ABMS.
Approaches Comparison
As mentioned previously, there are few studies that compare the Gillespie algorithm with ABMS. Most
of these studies regard research in economic models and immunology. To the best of our knowledge there
is no literature regarding the direct comparison of these methods to early-stage interactions between
the immune system and tumour cells. This section describes relevant researches in several areas, which
provided further insights into the gaps in the current literature and the research questions addressed in
this paper.
There are a few attempts of re-conceptualizing agent-based models into simpler stochastic models
of complex systems in economics. For instance, Daniunas et al. [27] start from simple models with
established agent-based versions (which they named “the model’s microscopic version”) and try to obtain
an equivalent macroscopic behavior. They consider microscopic and macroscopic versions of the herding
model proposed by Kirman [28] and the diffusion of new products, proposed by Bass in [29]. They
conclude that such simple models are easily replicated in a stochastic environment. In addition, the
authors state that for the economics field, only very general models, such as those studied in their article,
have well established agent-based versions and can be described by stochastic or ordinary differential
equations. However, as the complexity of the microscopic environment increases, it becomes challenging
to obtain resembling results with stochastic simulations and further developments need to be pursuit.
Furthermore, the authors debate that the ambiguity present in the microscopic description in complex
systems is an objective obstacle for quantitative modeling and needs further studying.
Stracquadanio et al. [30] investigate the contributions of ABMS and the Gillespie method for immune
modelling. The authors, however, do not apply both methods to the same problem. Instead, for the
first approach, they chose to investigate a large-scale model involving interactions of immune cells and
molecules. This model’s objective was to simulate the immune elements interplay over time. For the
Gillespie approach, the authors investigate a stochastic viral infection model. The authors point out
three factors that play a major role in the modeling outcome when comparing ABMS and Gillespie:
simulation time, model precision and accuracy, and model applicability. Regarding time, the authors
state that stochastic models implemented with the Gillespie algorithm are preferred. On the other hand,
ABMS permits more control over simulation runtime as it keeps record of the behavior of each single entity
involved in the system. Regarding applicability, the authors argue that traditional Gillespie methods do
not account for spatial information, which can be detrimental to the model accuracy given the fact that
many immune interactions occur within specific spatial regions of the simulation environment.
Karkutla [31] compares two biological simulators: GridCell, which is a stochastic tool based on Gille-
spie’s, and his new developed ABMSim, which is a simulation tool based on ABMS. GridCell was de-
veloped to overcome the issues in traditional Gillespie’s, as pointed out by Stracquadanio et al. [30].
It is a stochastic tool able to tackle non-homogeneity effectively by addressing issues of crowding and
localization. In GridCell, however, the problem of tracking individual behaviour and determining par-
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issues. GridCell has been compared with ABMSim qualitatively and quantitatively and the two tools
have produced similar results in the author experiments.
In our work we further study the differences between the approaches outcomes and investigate whether
under different problem characteristics for early-stage cancer we still obtain similar results. In the next
section we introduce the methodology used to conduct our investigations.
Materials and Methods
This section introduces the research methodology used for the development of our simulation models and
for the experimentation performed in the following sections. As mentioned previously, our investigations
concern the use of three cases to answer research questions regarding the application of the Gillespie
algorithm and ABMS interchangeably for early-stage cancer models. For each case study, there is a well
established ODE model from the literature and its correspondent agent-based model, that we previously
developed in [1]. The ODE model simulations are implemented using the ODE solver module from
MATLAB (2011).
The Gillespie algorithm is implemented by the direct conversion of the original mathematical equations
into reactions and simulating them under the COPASI 4.8 (Build35) simulator environment. The method
used for the stochastic simulations is the Gillespie algorithm adapted using the next reaction method [32],
with interval sizes of 0.1, integration interval between 0 and 1 and maximum internal steps of 106.
ABMS is a modelling and simulation technique that employs autonomous agents that interact with
each other. The agents’ behaviour is described by rules that determines how they learn, interact and
adapt. The overall system behaviour is given by the agents individual dynamics as well as their inter-
actions. Our agent-based models are implemented using the AnyLogicTM 6.5 educational version (XJ
Technologies 2010) [33]. This approach is developed by using state charts and tables containing each agent
description. The state charts show the different possible states of an entity and define the events that
cause a transition from one state to another. In order to facilitate the understanding of the agent-based
model, we reproduce here the models developments, which were based on [1] 1.
Methodology for Results Comparison
As the Gillespie and ABMS are both stochastic simulation methods, we ran five hundred replications for
each case study and calculated the mean values for the outputs. For all approaches, the rates (for cellular
death, birth, etc.) employed were the same as those established by the mathematical model.
In addition, in order to investigate any statically significant differences between the ABMS and Gille-
spie techniques for the case studies, we implement a mixed effect model. This is a type of regression
that considers both fixed and random effects. This method accounts for correlation caused by repeating
the measure over time (i.e., the tumour cell count is correlated over time for each simulation run). The
mixed effect analysis was implemented in the programming language R using the package NLME [34].
As a mixed effect model requires finding parameters for a regression model, it is not suitable when
considering the whole time period. This is because in cases 2 and 3 the tumour dynamics has a damping
oscillation and the function describing this dynamics is unknown (see pages 9 and 11). Instead, the
sequence of local maxima and minima are used. It can been seen that these are converging and any
statistical deviation between these sequences for the different simulation techniques indicate differences
between the output of the techniques. If the simulations from the ABMS and the Gillespie technique
come from the same distribution, then there would be no statistical difference between the maxima and
minima over time. Therefore, we investigate two null hypotheses. The first is that the function of local
maxima is the same for the ABMS and the Gillespie algorithm simulations. And the second is that the
1The ABMS and Gillespie models are available for download in http://anytips.cs.nott.ac.uk/wiki/index.php/Resources
5function of local minima is the same for the ABMS and the Gillespie algorithm simulations. We use a
1% significance level.
There is no standard technique for estimating the required sample size for non-linear mixed effect
models for a defined power when the measure of effect is known [35] . Therefore, the simulations are run
500 times as this will increase the statistical power and increase the probability of a true positive in the
statistical analysis. A false negative is still possible if there is only a small effect size, but if the effect is
small, it is of less interest.
Case 1: Interactions between Tumour Cells and Generic Effector Cells
The first case considers tumour cells growth and their interactions with general immune effector cells, as
defined in [8]. According to the model, effector cells search and kill the tumour cells inside the organism.
They proliferate proportionally to the number of existing tumour cells. As the quantities of effector cells
increase, their capacity of eliminating tumour cells is augmented. Immune cells proliferate and die per
apoptosis, which is a programmed cellular death. In the model, cancer treatment is also considered and
it consists of injections of new effector cells in the organism.
Mathematically, the interactions between tumour cells and immune effector cells are defined as fol-
lows [8]:
dT
dt
= Tf(T )− dT (T,E) (1)
dE
dt
= pE(T,E)− dE(T,E)− aE(E) + Φ(T ) (2)
where
• T is the number of tumour cells,
• E is the number of effector cells,
• f(T ) is the growth of tumour cells,
• dT (T,E) is the number of tumour cells killed by effector cells,
• pE(T,E) is the proliferation of effector cells,
• dE(T,E) is the death of effector cells when fighting tumour cells,
• aE(E) is the death (apoptosis) of effector cells,
• Φ(T ) is the treatment or influx of cells.
The Kuznetsov model [8] defines the functions f(T ), dT (T,E), pE(E, T ), dE(E, T ), aE(E) and Φ(t)
as shown below:
f(T ) = a(1− bT ) (3)
dT (T,E) = nTE (4)
pE(E, T ) =
pTE
g + T
(5)
dE(E, T ) = mTE (6)
6aE(E) = dE (7)
Φ(t) = s (8)
Table 2 shows the mathematical equations converted into reactions and their respective rate laws per
cell.
In the agent-based model there are two classes of agents, the tumor cells and the effector cells, as
described in [1]. Table 3 shows the parameters and behaviours corresponding to each agent state. For
our agents, state charts are used to represent the different states each entity is in. In addition, transitions
are used to indicate how the agents move from one state to another. Events are also employed and they
indicate that certain actions are scheduled to occur in the course of the simulation, such as injection
of treatment. The state chart representing the tumour cells is shown in Figure 1(a), in which an agent
proliferates, dies with age or is killed by effector cells. In addition, tumour cells contribute to damage to
effector cells, according to the same rate as defined by the mathematical model (Table 4). Figure 1(b)
shows the state chart for the effector cells. In the figure, the cell is either alive or dead by age or apoptosis.
While the cell is alive, it is also able to kill tumour cells and proliferate. In the transition rate calculations,
the variable TotalTumourCells corresponds to the total number of tumour cell agents; and the variable
TotalEffectorCells is the total number of effector cell agents. In the simulation model, apart from the
agents, there is also an event – namely, treatment – which produces new effector cells with a rate defined
by the parameter s.
Experimental Design for the Simulations
Similarly to the experiments from [1], four scenarios are investigated. The scenarios have different rates
for the death of tumour cells (defined by parameter b), effector cells apoptosis (defined by parameter d)
and different treatments (parameter s). The values for these parameters are obtained from [6] (Table 5).
In the first three scenarios, cancer treatment is considered, while the fourth case does not consider any
treatment. The simulations for the ABMS and the Gillespie algorithm are run five hundred times and
the mean values are displayed as results.
Results and Discussion
Figure 2 shows the results of our experiments. In the first column we display the results from the ODE
model for guidance. The second column shows the results from the Gillespie algorithm and the third
column presents the ABMS results. Each row of the figure represents a different scenario.
Results for Scenario 1 appear similar for the three approaches, although the effector cells curve from
the ABMS show more variability. To evaluate whether the results are significantly different for the two
simulation methods, we apply a mixed effect model. The null hypothesis is that there is no significant
difference between the methods (and therefore there will be no significant fixed effect for the method
type). We use a 1% significance level. We are testing the similarity for the population of effector cells.
The effector cells follow a dynamic similar to 1/x for the time between 1 and 100:
f(t) =
5
a× (t+ b)
(9)
We apply a mixed-effect model where the simulation run is considered to have a random effect on the
parameter a and the simulation method has a fixed effect on a and b. The results are presented in Table
6. At a 1% significance level the results of the two techniques are significantly different as the p-values
for the fixed effect of the method on the parameters are less than 0.1.
7We believe that the variability observed in the ABMS and Gillespie curves, given their stochasticity,
also influenced the statistical test results. The number of effector cells for all simulations follow a similar
pattern, although the similarity hypothesis was rejected. This variability of Gillespie and ABMS is very
evident with regards to the effector cells population as the size of the populations involved in the first
scenario is relatively small, which increases the impacts of stochasticity in the outcomes.
Results for scenario 2 are shown in the second row of Figure 2. The outcomes seem fairly different. By
observing the ODE results, during about the first ten days, the tumour cells decrease and then grow up
to a value of about 240 cells, subsequently reaching a steady-state. This initial decrease is also observed
in both Gillespie and ABMS curves. However, only the Gillespie method shows a similar increase in the
numbers of tumour cells when compared to the ODEs. Similarly to the previous scenario, the Gillespie
and ABMS simulation curves present an erratic behaviour throughout the simulation days. There is,
however, an unexpected decay of tumour cells over time in the ABMS simulation, which does not happen
in the Gillespie outcome. We believe the difference observed in the ABMS is due to the the individual
characteristics of the agents and their growth/death rates attributed to their instantiation. While both
ODEs and Gillespie are compartmental models and therefore they apply the model rates to the cells
population, ABMS on the contrary, employs these rates in an individual basis. As the death rates of the
tumour cells agents are defined according to the mathematical model, when the tumour cell population
grows, the newborn tumour cells have higher death probabilities, which leads to a considerable number of
cells dying out. This indicates that the individual behaviour of cells can lead to a more chaotic behaviour
when compared to the aggregate view observed in the compartmental simulation.
For scenarios 3 and 4, shown in third and fourth rows of Figure 2, respectively, the results for the
three approaches differ completely. The differences are even more evident for the tumour cells outcomes.
The ODEs results for scenario 3 reveal that tumour cells decreased as effector cells increased, following a
predator-prey trend curve. For the ABMS, however, the number of effector cells decreased until a value
close to zero was reached, while the tumour cells numbers were very different from those in the ODEs
results. The ODE pattern noticed was possible given its continuous character. In the ODE simulation
outcome curve for the effector cells it is therefore possible to observe, for instance, that after sixty days
the number of effector cells ranges between one and two. These values could not be reflected in the
ABMS simulation, as it deals with integer values. Similarly, the Gillespie approach outcomes did not
resemble those from the ODE model. There is more variability in the tumour cells curve than in the
ABMS outcomes, although the number of tumour cells also reaches zero after around sixty days.
In the fourth scenario, although effector cells appear to decay in a similar trend for both approaches,
the results for tumour cells vary largely. In the ODE simulation, the numbers of effector cells reached
a value close to zero after twenty days and then increased to a value smaller than one. For the ABMS
simulation, however, these cells reached zero and never increased again. For the Gillespie model results,
a similar pattern as that from the ABMS model occurs, although there seems to be less variance in the
outcome curve. In addition, the mean numbers for tumour cells for the Gillespie approach seem smaller
that those observed in the ABMS.
Summary
An outcome comparison between an ABMS and a Gillespie algorithm model was performed for case
study 1. We considered an ODE model of tumour cells growth and their interactions with general
immune effector cells as the baseline for results validation. Four scenarios considering small population
numbers were investigated and results from ABMS and Gillespie were different for both populations for
all scenarios. Furthermore, both approaches differed largely from the original mathematical outcomes.
These results indicate that, for this case study, the stochasticity applied to the population as a whole
when compared to that applied to the individual has a higher impact given the small population sizes.
The result analysis also reveals that conceptualizing the stochastic approaches from the mathematical
equations does not always produce statistically similar outputs.
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Case two regards the interactions between tumour cells, effector cells and the cytokine IL-2. It extends
the previous study as it considers IL-2 as molecules mediating the immune response towards tumour cells.
These molecules interfere in the proliferation of effector cells, which occurs proportionally to the number
of tumour cells in the system. For this case, there are two types of treatment, the injection of effector
cells or the addition of cytokines.
The mathematical model used in case 2 is obtained from [9]. The model’s equations described bellow
illustrate the non-spatial dynamics between effector cells (E), tumour cells (T) and the cytokine IL-2
(IL):
dE
dt
= cT − µ2E +
p1EIL
g1 + IL
+ s1 (10)
Equation 10 describes the rate of change for the effector cell population E [9]. Effector cells grow
based on recruitment (cT ) and proliferation (p1EIL
g1+IL
). The parameter c represents the antigenicity of the
tumour cells (T) [5,9]. µ2 is the death rate of the effector cells. p1 and g1 are parameters used to calibrate
the recruitment of effector cells and s1 is the treatment that will boost the number of effector cells.
dT
dt
= a(1 − bT )−
aaET
g2 + T
(11)
Equation 11 describes the changes that occur in the tumour cell population T over time. The term
a(1 − bT ) represents the logistic growth of T (a and b are parameters that define how the tumour cells
will grow) and aaET
g2+T
is the number of tumour cells killed by effector cells. aa and g2 are parameters to
adjust the model.
dIL
dt
=
p2ET
g3 + T
− µ3IL + s2 (12)
The IL-2 population dynamics is described by Equation 12. p2ET
g3+T
determines IL-2 production using
parameters p2 and g3. µ3 is the IL-2 loss. s2 also represents treatment. The treatment is the injection
of IL-2 in the system.
Table 7 shows the mathematical model converted into reactions for the Gillespie algorithm model.
The first column of the table displays the original mathematical equation, followed by the equivalent
reactions and rate laws in the subsequent columns.
As described in [1], the agents represent the effector cells, tumour cells and IL-2. Their behaviours
are shown in Table 8. The state charts for each agent type are shown in Figure 3. The ABMS model
rates are the same as those defined in the mathematical model and are given in Table 9. In the transition
rate calculations, the variable TotalTumour corresponds to the total number of tumour cell agents, the
variable TotalEffector is the total number of effector cell agents and TotalIL 2 is the total number of
IL-2 agents. In the simulation model, apart from the agents, there are also two events: the first event
adds effector cell agents according to the parameter s1 and the second one adds IL-2 agents according to
the parameter s2.
Experimental Design for the Simulation
The experiment is conducted assuming the same parameters as those of the mathematical model (Ta-
ble 10). For the ABMS and the Gillespie algorithm model, the simulation is run five hundred times
and the average outcome value for these runs is collected. Each run simulates a period equivalent to
six hundred days, following the same time span used for the numerical simulation of the mathematical
model.
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The results obtained are shown in Figure 4 for tumour cells (left), effector cells (middle) and IL-2 (right),
respectively. As the figure reveals, the results for all populations are analogous; the growth and decrease
of all populations occur at similar times for all approaches. ABMS has a little more variability in the
results, specially regarding IL-2. We believe that for this case, the large population sizes (around 104)
produce a lower variability in the outcomes of the stochastic approaches. For statistical comparison,
results were contrasted by applying a non-linear mixed effect model, as shown next.
The local maxima sequence follows a second order polynomial function of the form:
f(t) = c+ a(t− b)2 (13)
The local minima sequence follows a second order polynomial function of the form:
f(t) = c− a ∗ (t− b)2 (14)
For the mixed-effect model, we consider a and b to have fixed effects based on the type of simulation
(e.g., ABMS or Gillespie algorithm) and a and b to have random effects based on the individual simulation
run. The results of the mixed effect model are presented in Tables 11 and 12. It can been seen that
there is a significant difference between the a and b parameter values for the two different techniques.
We therefore reject the null hypotheses and accept that there is a significance difference between the
two techniques in terms of the sequence of maxima and sequence of minima, at a 1% significance level.
Furthermore, the results show that the ABMS simulations tend to have larger local maxima and smaller
local minima, which is clear in Figure 5.
Summary
Interactions between tumour cells, effector cells and the cytokine IL-2 were considered to investigate the
potential differences and similarities of ABMS and Gillespie algorithm outcomes. Statistical comparison
between the Gillespie and the ABMS results show a significant difference in the outcomes. Compared
to the original ODE model used as validation, ABMS displayed a little more variability in the results,
whereas the Gillespie algorithm followed mostly the same patterns as those produced by the ODEs for
all populations in the simulation. As for these simulations a bigger number of individuals was required,
it was also observed that, regarding the use of computational resources, ABMS was far more time- and
memory-consuming than the Gillespie approach.
Case 3: Interactions between Tumour Cells, Effector Cells, IL-2 and TGF-β
Case study three comprises interactions between tumour cells and immune effector cells, as well as
the immune-stimulatory and suppressive cytokines IL-2 and TGF-β [5]. According to the ODE model
developed by Arciero et al. in [5], TGF-β stimulates tumour growth and suppresses the immune system
by inhibiting the activation of effector cells and reducing tumour antigen expression.
The mathematical model is described by the differential equations below:
dE
dt
=
cT
1 + γS
− µ1E +
(
p1EI
g1 + I
)(
p1 −
q1S
q2 + S
)
(15)
Equation 15 describes the rate of change for the effector cell population E. According to [5], effector
cells are assumed to be recruited to a tumour site as a direct result of the presence of tumour cells. The
parameter c in cT1+γS represents the antigenicity of the tumour, which measures the ability of the immune
system to recognize tumour cells. The presence of TGF-β (S) reduces antigen expression, thereby limiting
the level of recruitment, measured by the inhibitory parameter γ. The term µ1E represents loss of effector
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cells due to cell death. The proliferation term
(
p1EI
g1+I
)(
p1 −
q1S
q2+S
)
asserts that effector cell proliferation
depends on the presence of the cytokine IL-2 and is decreased when the cytokine TGF-β is present. p1
is the maximum rate of effector cell proliferation in the absence of TGF-β, g1 and q2 are half-saturation
constants, and q1 is the maximum rate of anti-proliferative effect of TGF-β.
dT
dt
= aT
(
1−
T
K
)
−
aaET
g2 + T
+
p2ST
g3 + S
(16)
Equation 16 describes the dynamics of the tumour cell population. The term aT
(
1− T
K
)
represents a
logistic growth dynamics with intrinsic growth rate a and carrying capacity K in the absence of effector
cells and TGF-β. The term aaET
g2+T
is the number of tumour cells killed by effector cells. The parameter
aa measures the strength of the immune response to tumour cells. The third term
p2ST
g3+S
accounts for
the increased growth of tumour cells in the presence of TGF-β. p2 is the maximum rate of increased
proliferation and g3 is the half-saturation constant, which indicates a limited response of tumour cells to
this growth-stimulatory cytokine [5].
dI
dt
=
p3ET
(g4 + T )(1 + αS)
− µ2I (17)
The kinetics of IL-2 are described in equation 17. The first term p3ET(g4+T )(1+αS) represents IL-2 produc-
tion which reaches a maximal rate of p3 in the presence of effector cells stimulated by their interaction
with the tumour cells. In the absence of TGF-β, this is a self-limiting process with half-saturation con-
stant g4 [5]. The presence of TGF-β inhibits IL-2 production, where the parameter α is a measure of
inhibition. Finally, µ2I represents the loss of IL-2.
dS
dt
=
p4T
2
θ2 + T 2
− µ3S (18)
Equation 18 describes the rate of change of the suppressor cytokine, TGF-β. According to [5],
experimental evidence suggests that TGF-β is produced in very small amounts when tumours are small
enough to receive ample nutrient from the surrounding tissue. However, as the tumour population grows
sufficiently large, tumour cells suffer from a lack of oxygen and begin to produce TGF-β in order to
stimulate angiogenesis and to evade the immune response once tumour growth resumes. This switch in
TGF-β production is modelled by the term p4T
2
θ2+T 2 , where p4 is the maximum rate of TGF-β production
and τ is the critical tumour cell population in which the switch occurs. The decay rate of TGF-β is
represented by the term µ3S.
Table 13 presents the Gillespie algorithm model used for our simulations. The model was obtained
by converting the ODEs into reaction equations.
The agents established for the ABMS represent the effector cells, tumour cells, IL-2 and TGF-β
populations, as described in [1]. The agents’ behaviour is defined in Table 14. The state charts for each
agent type are illustrated in Figure 6.
The ABMS model rates corresponding to the mathematical model are given in Table 15. In the
transition rate calculations, the variable TotalTumour corresponds to the total number of tumour cell
agents; the variable TotalEffector is the total number of effector cell agents, TotalIL 2 is the total
number of IL-2 agents and TotalTGFBeta is the total TGF-β agents. This model does not include
events.
Experimental design for the simulation
The experiment is conducted assuming the same parameters as those defined for the mathematical model
(Table 16). Similarly to the previous case studies, for the ABMS and Gillespie models the simulation is
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run five hundred times and the average outcome value for these runs is displayed as result. Each run
simulates a period equivalent to six hundred days, following the time interval used for the numerical
simulation of the mathematical model. The parameters used for the simulations of all approaches are
shown in Table 16.
Results and discussion
The mean results of 500 runs for the Gillespie algorithm and the ABMS contrasted with the ODE model
are shown in Figure 7. The left graph in the figure presents the outcomes for tumour cells; the graph
in the middle shows the outputs for effector cells; the graph on the right shows the mean IL-2 outcomes
(the TGF-β results have some particularities and therefore are discussed next). The figure shows that
both Gillespie and ABMS do not match properly the original results from the mathematical model.
Additionally, ABMS is far more dissimilar than what was anticipated. In order to understand why the
mean values were that much different from what was expected, we plotted fifty individual runs for each
approach, as shown in figures 8, 9, 10 and 12. These runs illustrate the variations observed in both ABMS
(left side of the figures) and Gillespie (right side of the figures) approaches, due to its stochastic character.
In the figures, the ODE model results were also plotted (dashed black line) in order to highlight the range
of variation produced by the stochastic approaches. As it can be observed in the figures, both Gillespie
and ABMS outcomes produce various slightly distinct starting times for the growth of populations. In
addition to these variations, for a few runs the populations in ABMS decreased to zero, as previously
reported in [1]. This behaviour was not reflected in the Gillespie algorithm results. This indicates that
it is not always possible to replicate similar results within both approaches.
The use of ABS modelling has therefore led to the discovery of additional “rare” patterns, which we
would have not been able to derive by using analytical methods or the dynamic Monte Carlo method, i.e.
the Gillespie algorithm. These “extreme cases” found by ABMS suggest that there might be circumstances
where the tumour cells are completely eliminated by the immune system, without the need of any cancer
therapies.
We believe that ABMS when compared to Gillespie produces extra patterns because of the agents
individual behaviour and their interactions. While ODEs and the Gillespie algorithm always use the
same values for the parameters over the entire population aggregate, ABMS rates vary with time and
number of individuals. Each agent is likely to have distinct numbers for their probabilities and therefore
have its own memory of past events (Gilespie, however, does not encompass individual memory for its
elements). The agents individual interactions, which give raise to the overall behaviour of the system,
are also influenced by the scenario determined by the random numbers used. By running the ABMS
multiple times with different sets of random numbers, the outcomes vary according to these sets and the
emerging interactions of the agents also produce the rare outcome patterns.
For further statistical comparison of the results that follow the same pattern of behaviour for ABMS
and Gillespie, a mixed-effect model is used. In 236 of the 500 ABMS simulations the tumour cell popula-
tion dies out early in time. The remaining 264 ABMS simulations (where the tumour cell population does
not die out over the [0,600] time period) is compared with the 500 Gillespie simulations by a non-linear
mixed effect model.
The local maxima sequence follows a second order polynomial function of the form:
f(t) = 40311 + a(t− b)2 (19)
The local minima sequence follows a second order polynomial function of the form:
f(t) = a ∗ (t− b)2 (20)
For the mixed-effect model we considered a and b to have fixed effects based on the type of simulation
(e.g., ABMS or Gillespie algorithm) and a and b to have random effects based on the individual simulation
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run. The results of the mixed effect model are presented in Tables 17 and 18. It can been seen that
there is a significant difference between the a and b parameter values for the two different techniques.
We therefore reject the null hypotheses and accept that there is a significance difference between the two
techniques in terms of the sequence of maxima and sequence of minima, at a 1% significance level.
Tables 17—18 and Figure 11 show that the sequence of local maxima of the ABMS diverge from
that of the Gillespie algorithm over time. In the ABMS the tumour cells tend to increase to a larger
count than the Gillespie algorithm simulations causing the function of local maxima for the ABMS to
be significantly greater than the Gillespie. A possible explanation for this, as mentioned previously, is
the fact that agents have memory and therefore the rates (death, proliferation, etc) for a certain cell are
determined by the cells (and their proportions) present in the system at the moment the cell was created.
For the Gillespie algorithm, instead, the rates are applied globally to the entire population and remain
constant over the simulation course. Consequently, for Gillespie, the individuals do not keep a record of
the previous population dynamics. This explanation is supported by the observation that the function
describing the sequence of local minima of the ABMS is significantly lower than the Gillespie algorithm
over time, as the same argument would account for the ABMS simulations reaching lower levels.
Regarding the TGF-β outcomes, the ODEs results reveal numbers smaller than one (Figure 12 on the
right), which is not possible to achieve with the ABMS and the Gillespie algorithm. The simulation results
regarding these molecules are therefore completely different for both stochastic approaches. By observing
the multiple runs graph of ABMS, however, results indicate that the TGF-β grows at around 100 and 200
days, which resembles what occurs in the ODE simulation for the first two peaks of TGF-β concentration.
This suggests that ABMS, as opposite to Gillespie, is capable of capturing some of the behaviours of the
analytical results even when the outputs are different. We believe that these observations need to be
further investigated in order to determine whether this happens in other case studies. In addition, it
is necessary to investigate in what circumstances and range of values ABMS is still capable to reflect
behaviours of numbers smaller than one agent present in the ODE model.
Summary
The third case study simulations investigated interactions between effector cells, tumour cells and two
types of cytokines, namely IL-2 and TGF-β. When compared to the original ODE results, both Gillespie
algorithm and ABMS produced more variability in the outcomes. For each of the five hundred runs, a
slightly different start of population growth was observed. In addition, ABMS produced extra patterns
not observed in the original mathematical model and in the Gillespie results. These extra patterns
have been reported previously in [1] and with the present work we wanted to find out whether the
Gillespie algorithm simulation results would be as informative. This indicates that, for this case study,
both methods should not be employed interchangeably, as some extra possible population patterns of
behaviour might not be uncovered without ABMS. We believe that these emergent examples occur due
to the individual interactions of the agents and their chaotic character. With these results, we answer our
third research question that it is not possible in this case to obtain extreme patterns using the Gillespie
algorithm.
Conclusions
In this work, we employed three case studies to investigate circumstances where we can use ABMS
and the Gillespie algorithm interchangeably. We aimed at reproducing the variability embedded in the
ABMS systems to the mathematical formulation and verify whether results resemble. Current literature
regarding the comparison of the Gillespie algorithm and ABMS is scarce and we wanted therefore to
answer the questions: (1) Does the Gillespie algorithm produce similar results to ABMS? (2) Can these
two methods be used interchangeably for our case studies? (3) Does the Gillespie algorithm also find the
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extra patterns revealed by the ABMS in the third case study? The case studies investigated regarded
models with different characteristics, such as population sizes, modelling effort demanded and model
complexity.
The first case study involved interactions with general immune effector cells and tumour cells. Four
different scenarios regarding distinct sets of parameters were investigated and in the first three scenarios
treatment was included. ABMS and Gillespie produced different results for all scenarios. It appears that
two major characteristics of this model influenced the differences obtained: (1) The small quantities of
individuals considered in the simulations (especially regarding the effector population size, which was
always smaller than ten) that significantly increased the variability of both stochastic approaches; and
(2) the stochasticity of the Gillespie algorithm is applied to the aggregates, while in the ABMS there is
individual variability.
Case study 2 referred to the investigation of a scenario containing interactions between effector cells,
cytokines IL-2 and tumour cells. For this case the Gillespie and ABMS approaches produced similar
outcome curves, which also matched the pattern of behaviour of the mathematical model used for vali-
dation. As populations sizes had a magnitude of 104 individuals, the erratic behaviour of both stochastic
approaches was no longer evident in the outcomes. However, although results seemed similar, further
statistical tests reject their similarity hypothesis. It was observed that, for case 2 in general, ABMS
simulation outcome curves tend to have larger local maxima and smaller local minima.
Case study 3 includes the influence of the cytokine TGF-β in the interactions between effector cells,
cytokines IL-2 and tumour cells from the previous case. The simulation outcomes for the ABMS were
mostly following the same pattern as those produced by the Gillespie algorithm, although the results
were statistically different. In addition, Gillespie failed to replicate the alternative outcomes found by the
ABMS. This indicates that for this case study the ABMS results are more informative, as they illustrate
another set of possible dynamics to be validated in real-world. Furthermore, ABMS was also able to
indicate two peaks where TGF-β concentrations have grown, although the corresponding values in the
mathematical model were smaller than one.
In response to our research questions, we conclude that regarding the interchangeable use of Gillespie
and ABMS, population size has a positive impact on result similarity. This means that bigger populations
tend to result in close simulation output patterns. However, the stochasticity of both approaches and the
memory present in the ABMS produce outcome differences which are statistically significant, although
visually the outcomes look similar. Finally, the emergent behaviour of ABMS can contribute additional
insight (extra patterns), which was not obtained by the aggregate stochasticity present in Gillespie, given
its incapacity of retaining memory of past events for their elements.
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Figure Legends
(a) Tumour cell agent (b) Effector cell agent
Figure 1. ABMS state charts for case 1
Figure 2. Results for the first case study
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Figure 3. ABMS state charts for the agents of case 2
Figure 4. Results for the second case study: tumour cells, effector cells and IL-2
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Figure 5. Illustration of the regression models fit for the sequences of the local maxima
and local minima for the two different simulation techniques. The Gillespie simulations
are plotted in purple with the mixed effect models plotted in blue. The ABMS simulation
runs are plotted in orange with the mixed effect models plotted in red.
Figure 6. ABMS state charts for the agents of case 3
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Figure 7. Results for the third case study: mean values of tumour cells, effector cells and
IL-2
Figure 8. Results for the third case study: 50 runs for tumour cells
Figure 9. Results for the third case study: 50 runs for effector cells
20
Figure 10. Results for the third case study: 50 runs for IL2 cells
Figure 11. Illustration of the regression models fit for the sequences of the local maxima
and local minima for the two different simulation techniques. The Gillespie simulations
are plotted in purple with the mixed effect models plotted in blue. The ABMS simulation
runs are plotted in orange with the mixed effect models plotted in red.
21
Figure 12. Results for the third case study: 50 runs for TGF-β. The figure on the right is
a zoomed version of the figure in the centre.
Tables
Table 1. Case studies considered
Case Study Number of populations Population size Complexity
1) Tumour/Effector 2 5 to 600 Low
2) Tumour/Efector/IL-2 3 104 Medium
3) Tumour/Effector/IL-2/ TGF-β 4 104 High
Table 2. Reactions for case 1
Phenomenon Reaction equation Rate law (per cell)
Tumour cell birth T → 2× T aT
Tumour cell death 2 ∗ T → T abT 2
Tumour cell death by effector cells T + E → E nTE
Effector proliferation E → 2× E;T pTE
g+T
Effector death by fighting tumour T + E → T mTE
Effector death E → dE
Effector supply → E s
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Table 3. Agents’ parameters and behaviours for case 1
Agent Parameters Reactive behaviour Proactive behaviour
Tumour Cell
a and b Dies (with age)
a and b Proliferates
m Damages effector cells
n Dies killed by effector cells
Effector Cell
m Dies (with age)
d Dies per apoptosis
p and g Proliferates
s Is injected as treatment
Table 4. Transition rates calculations from the mathematical equations for case 1
Agent Transition Mathematical equation Transition rate
Tumour Cell
proliferation aT (1− Tb) a− (TotalTumour.b)
death aT (1− Tb) a− (TotalTumour.b)
dieKilledByEffector nTE n.T otalEffectorCells
causeEffectorDamage mTE m
Effector Cell
Reproduce pTE
g+T
p.TotalTumourCells
g+TotalTumourCells
DiePerAge dE d
DiePerApoptosis mTE message from tumour
Table 5. Simulation parameters for the four different scenarios under investigation. For
the other parameters, the values are the same in all experiments, i.e. a = 1.636, g = 20.19,
m = 0.00311, n = 1 and p = 1.131.
Scenario b d s
1 0.002 0.1908 0.318
2 0.004 2 0.318
3 0.002 0.3743 0.1181
4 0.002 0.3743 0
Table 6. The fixed parameter values returned by the mixed-effect model and their
significance.
Method Parameter Value std error p-value
ABS a 0.03393 0.0004397 0
SODE a 0.02925 0.0006126 0
ABS b 41.15847 0.6149638 0
SODE b 52.07957 1.0328222 0
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Table 7. Reactions for case 2
Name Reaction equation Rate law (per cell)
Effector cell recruitment → E;T cT
Effector cell proliferation E → 2× E; I p1E.IL(g1+IL)
Effector cell death E → µ2E
Effector cell supply → E s1
Tumour cell birth T → 2× T aT
Tumour cell death 2 ∗ T → T abT 2
Tumour cell death by effector cells T + E → E;T aaTE
g2+T
IL-2 production → I;ET p2ET
g3+T
IL-2 decay I → µ3
IL-2 supply → I s2
Table 8. Agents’ parameters and behaviours for case 2
Agent Parameters Reactive behaviour Proactive behaviour
Effector Cell
mu2 Dies
p1 and g1 Reproduces
c Is recruited
s1 Is injected as treatment
p2 and g3 Produces IL-2
aa and g2 Kills tumour cells
Tumour Cell
a and b Dies
a and b Proliferates
aa and g2 Dies killed by effector cells
c Induces effector recruitment
IL-2
p2 and g3 Is produced
mu3 Is lost
s2 Is injected
Table 9. Transition rates calculations from the mathematical equations for case 2
Agent Transition Mathematical equation Transition rate
Effector Cell
Reproduce p1.ILE
g1+IL 2
p1.TotalIL 2.TotalEffector
g1+TotalIL 2
Die µ2E mu2
killTumour aaET
g2+T aa
TotalTumour
g2+TotalTumour
ProduceIL2 p2ET
g3+T
p2.TotalTumour
g3+TotalTumour
Tumour Cell
Reproduce aT (1− bT ) a− (TotalTumour.b)
Die aT (1− bT ) a− (TotalTumour.b)
DieKilledByEffector aaTE
g2+T message from effector
IL-2 Loss µ3IL mu3
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Table 10. Parameter values for case 2
Parameter Value
a 0.18
b 0.000000001
c 0.05
aa 1
g2 100000
s1 0
s2 0
mu2 0.03
p1 0.1245
g1 20000000
p2 5
g3 1000
mu3 10
Table 11. The results of the mixed model for the sequence of local maxima in case study 2
Technique Parameter Value Std Error p-value
ABMS a 0.122 0.00073 0
Gillespie a 0.131 0.00102 0
ABMS b 442.249 1.160664 0
Gillespie b 432.243 1.52861 0
ABMS c 23149.344 23.67208 0
Gillespie c 22694.685 31.88635 0
Table 12. The results of the mixed model for the sequence of local minima in case study 2
Technique Parameter Value Std Error p-value
ABMS a 0.080 0.00033 0
Gillespie a 0.088 0.00047 0
ABMS b 462.004 1.12224 0
Gillespie b 444.888 1.46963 0
ABMS c 17118.133 25.43450 0
Gillespie c 17416.363 34.44740 0
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Table 13. Reactions for case 3
Name Equation Rate law (per cell)
Effector cell recruitment → E;TS c×T1+γ×S
Effector death E → µ1 × E
Effector proliferation T + E → E;T
(
p×I×E
g+I
)
×
(
p− ( q1×S
q2+S
)
Tumour cell growth T → 2× T a× T
Tumour cell death 2× T → T aT
2
K
Tumour cell death by effector cells T + E → E;T aaTE
g2+T
Tumour growth caused by TGF-β T → 2× T ;S p2×S×T
g3+S
IL-2 production → I;ETS p3×E×T(g4+T )(1+αS)
IL-2 decay I → µ2 × I
TGF-β production → I;T p4T
2
θ2+T 2
TGF-β decay S → µ3 × S
Table 14. Agents’ parameters and behaviours for case 3
Agent Parameters Reactive behaviour Proactive behaviour
Effector Cell
mu1 Dies
p1, g1, q1 and q2 Reproduces
c Is recruited
aa and g2 Kills tumour cells
Tumour Cell
a Dies
a Proliferates
aa and g2 Dies killed by effector cells
g3 and p2 Has growth stimulated
p4 and tetha Produces TGF-β
c Induces effector recruitment
IL-2
alpha, p3 and g4 Is produced
mu2 Is lost
TGF-β
p4 and tetha Is produced
mu3 Is lost
p2 and g3 Stimulates tumour growth
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Table 15. Transition rates calculations from the mathematical equations for case 3
Agent Transition Mathematical equation Transition rate
Effector Cell
Reproduce
p1IE
g1+I×
p1×TotalIL 2
g1+TotalIL 2×(
p1− q1S
q2+S
) (
p1− q1×TotalTGFBeta
q2+TotalTGFBeta
)
Die µ1E mu1
ProduceIL2 p3TE(g4+T )(1+alphaS)
p3.TotalTumour
(g4+TotalTumour)(1+alpha.TotalTGF )
KillTumour aaTE
g2+T
aa×TotalTumour×TotalEffector
g2+TotalTumour
Tumour Cell
Reproduce
(
aT
(
1− T1000000000
)) (
TotalTumour.a
(
1− TotalTumour1000000000
))
Die
(
aT
(
1− T1000000000
)) (
TotalTumour.a
(
1− TotalTumour1000000000
))
DieKilledByEffector aa.TE
g2+T message from effector
ProduceTGF p4T
2
teta2+T 2
p4.TumourCells
teta2+TumourCells2
EffectorRecruitment cT1+γS
c
1+gamma.TotaltGF
IL-2 Loss µ2I mu2
TGF-β
Loss µ3S mu3
stimulates
TumourGrowth p2T
g3+S
p2.TotalTGF
g3+TotalTGF
Table 16. Parameter values for case 3
Parameter Value
a 0.18
aa 1
alpha 0.001
c 0.035
g1 20000000
g2 100000
g3 20000000
g4 1000
gamma 10
mu1 0.03
mu2 10
mu3 10
p1 0.1245
p2 0.27
p3 5
p4 2.84
q1 10
q2 0.1121
theta 1000000
k 10000000000
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Table 17. The results of the mixed model for the sequence of local maxima in case study 3
Technique Parameter Value Std Error p-value
ABMS a 0.1354 0.001403 0
Gillespie a 0.2244 0.002242 0
ABMS b 747.8501 2.876438 0
Gillespie b 595.3515 3.338526 0
Table 18. The results of the mixed model for the sequence of local minima in case study 3
Technique Parameter Value Std Error p-value
ABMS a 0.01325 0.0002059 0
Gillespie a 0.01823 0.0002514 0
ABS b 37.33220 2.1334837 0
Gillespie b 5.93249 2.4013484 0
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